Frontiers | Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer

Multi-dimensional Biomarkers and Resistance Mechanism of Targeted Therapy and Immunotherapy in Lung Cancer

31k
Total downloads
85k
Total views and downloads

Download PDF Download EPUB

Articles

ORIGINAL RESEARCH

Published on 08 Oct 2021

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy

Lingling Li
Chenghui Pi
Xin Yan
Jiangyue Lu
Xuhui Yang
Chunyu Wang
Xiaoyan Li
Sujie Zhang
Zhibo Zhang
1 more
Yi Hu

doi 10.3389/fonc.2021.697865

8,322 views
20 citations

ORIGINAL RESEARCH

Published on 24 Sep 2021

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Toshiya Fujisaki
Satoshi Watanabe
Takeshi Ota
Kohei Kushiro
Yusuke Sato
Miho Takahashi
Aya Ohtsubo
Satoshi Shoji
Koichiro Nozaki
18 more
Toshiaki Kikuchi

doi 10.3389/fonc.2021.704475

2,803 views
17 citations

ORIGINAL RESEARCH

Published on 16 Sep 2021

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Anqi Lin
Hongman Zhang
Hui Meng
Ze Deng
Tianqi Gu
Peng Luo
Jian Zhang

doi 10.3389/fimmu.2021.667875

2,571 views
11 citations

ORIGINAL RESEARCH

Published on 26 Aug 2021

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer

Guangsheng Zhu
Ruifeng Shi
Yongwen Li
Zihe Zhang
Songlin Xu
Chen Chen
Peijun Cao
Hongbing Zhang
Minghui Liu
2 more
Jun Chen

doi 10.3389/fimmu.2021.670040

6,986 views
44 citations

REVIEW

Published on 06 Aug 2021

Tryptophan and Its Metabolites in Lung Cancer: Basic Functions and Clinical Significance

Chenwei Li
Hui Zhao

doi 10.3389/fonc.2021.707277

3,729 views
22 citations

CASE REPORT

Published on 03 Aug 2021

Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy

Chuchu Shao
Menghang Yang
Yingying Pan
Dacheng Xie
Bin Chen
Shengxiang Ren
Caicun Zhou

doi 10.3389/fimmu.2021.696749

2,748 views
20 citations

SYSTEMATIC REVIEW

Published on 14 Jul 2021

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Shuang Zhang
Shuang Li
Yanan Cui
Peiyan Zhao
Xiaodan Sun
Ying Cheng

doi 10.3389/fonc.2021.696010

2,009 views
6 citations

ORIGINAL RESEARCH

Published on 13 Jul 2021

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

Xinqing Lin
Haiyi Deng
Yilin Yang
Jianhui Wu
Guihuan Qiu
Suyang Li
Xiaohong Xie
Ming Liu
Zhanhong Xie
2 more
Chengzhi Zhou

doi 10.3389/fonc.2021.698832

4,671 views
43 citations

ORIGINAL RESEARCH

Published on 12 Jul 2021

A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

Ranpu Wu
Shaorong Yu
Jinjun Ye
Yimin Wang
Zhiting Zhao
Hongbing Liu
Yong Song

doi 10.3389/fonc.2021.692703

1,996 views
9 citations

ORIGINAL RESEARCH

Published on 24 Jun 2021

Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome

Xiao-Juan Chen
Aiqun Ren
Liang Zheng
En-Dian Zheng
Tao Jiang

doi 10.3389/fimmu.2021.651086

3,129 views
12 citations

ORIGINAL RESEARCH

Published on 09 Jun 2021

m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma

Junfan Pan
Zhidong Huang
Yiquan Xu

doi 10.3389/fonc.2021.657466

6,326 views
76 citations

ORIGINAL RESEARCH

Published on 04 Jun 2021

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

Ting Zhang
Xue Yang
Jing Zhao
Lixia Xia
Qiyuan Wang
Rui Jin
Lingxiao Zhou
Bin Zhang
Jun Zhao
2 more
Yang Xia

doi 10.3389/fonc.2021.690093

2,022 views
7 citations

Share on

Frontiers in Oncology

Cancer Immunity and Immunotherapy
Thoracic Oncology

Participating Journals

Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- 5.7 impact factor
- 9.8 citescore

Impact

85kTopic views
53kArticle views
31kArticle downloads

View impact

Submit your idea

Articles

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer

Tryptophan and Its Metabolites in Lung Cancer: Basic Functions and Clinical Significance

Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome

m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

Frontiers in Oncology

Participating Journals

Impact